Education
About Us
Working with TipRanks
Follow Us
Jasbir Seehra Insider Profile
4 Followers
Jasbir Seehra, Director at Eloxx Pharmaceuticals, holds ― shares in Eloxx Pharmaceuticals (Ticker: ELOX), holds 392.72K shares in Keros Therapeutics (Ticker: KROS). Most recently, Jasbir Seehra ― shares of Eloxx Pharmaceuticals on ― for an estimated value of ―.
Jasbir Seehra has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Jasbir Seehra holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Apr 13, 2020 - Apr 13, 2021
Return:+175.70%
The most profitable trade made by Jasbir Seehra
Jasbir Seehra's Trading History
Eloxx Pharmaceuticals
―
Director
―
―
Keros Therapeutics
Sep 05, 2025
CEO, Director
Uninformative Buy
―
$5.43M
List of latest transactions for each holding click on a transaction to see Jasbir Seehra's performance on stock
You May Also Like
Jasbir Seehra insider profile FAQ
What is the percentage of profitable transactions made by Jasbir Seehra?
The percentage of profitable transactions made by Jasbir Seehra is ―.
What is the average return per transaction made by Jasbir Seehra?
The average return per transaction made by Jasbir Seehra is ―.
What stocks does Jasbir Seehra hold?
Jasbir Seehra holds: ELOX, KROS stocks.
What was Jasbir Seehra’s latest transaction?
Jasbir Seehra latest transaction was an Uninformative Buy of ―.
What was Jasbir Seehra's most profitable transaction?
Jasbir Seehra’s most profitable transaction was an Informative Buy of KROS stock on April 13, 2020. The return on the trade was 175.70%.
What is Jasbir Seehra's role in Eloxx Pharmaceuticals?
Jasbir Seehra's role in Eloxx Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.